A 2.5 yr old sexually intact male vizsla was admitted to the Iowa State University Veterinary Teaching Hospital for persistent diarrhea, weight loss, and panhypoproteinemia. Examination revealed an emaciated condition and melena. Two masses were palpated in the cranial abdomen. Hematology and serum biochemistry exhibited a regenerative anemia and confirmed the presence of panhypoproteinemia, suggestive of a proteinlosing eneteropathy. Distinct areas of thickened intestinal wall and enlarged mesenteric lymph nodes were found on abdominal ultrasound. Cytology from those nodes showed the presence of suspected Cryptococcus spp., and infection was confirmed utilizing a cryptococcal antigen titer. Medical therapy with lipid-complexed amphotericin B and fluconazole was unsuccessful. Two surgical procedures were performed to remove the affected areas of intestine and lymph nodes, but the disease persisted as evidenced by a persistently elevated cryptococcal antigen titer. Terbinafine was prescribed, which resulted in complete resolution of clinical signs and a steadily decreasing cryptococcal antigen titer. Very few cases of intestinal cryptococcosis have been reported. In this case, infection resulted in a protein-losing enteropathy. In addition, this article describes the use of terbinafine in the treatment of intestinal cryptococcal infection in the dog, which has not been previously reported. 
Introduction
Cryptococcus neoformans and C. gatii are fungal organisms that infect many domesticated species, as well as humans. It is thought that infection is acquired environmentally, following inhalation of basidiospores. This yeast is not generally considered transmissible from one infected animal to either another animal or to a human. 1 The primary means of diagnosis of cryptococcosis is identification of the organism on aspirate or histopathology. An encapsulated basophilic organism with narrow-based budding is characteristic for Cryptococcus spp. 1 If the disease is suspected but no organisms are identified, fungal culture of the affected areas may yield diagnostic results. The organism has also been reported on fecal cytology. 2 Otherwise, the latex agglutination test is used for identifying the capsular antigen in serum. 3 Although that test has been proven to be sensitive, it has also been shown that the antigen can persist in the serum for an extended period of time after clinical disease has subsided. 4 One additional method of identification is through DNA sequencing, as was the case with this patient.
Cryptococcosis has been documented in the nasal cavity, central nervous system, optic nerve, cutis, bone, lymph nodes, and (uncommonly) in the gastrointestinal tract of various species. 1 The case presented here describes a unique presentation of proteinlosing enteropathy due to infection with C. neoformans located primarily within the small intestine and local lymph nodes, as well as utilization of a novel therapy, terbinafine, in the treatment protocol that resolved the enteropathy.
Case Report , and 6% hetastarch c transfusions.
Abdominal radiographs were performed, which revealed de- These organisms were most consistent with Cryptococcus spp.
( Figure 1 ). but subsequently decreased to 3.6 g/dL). Albumin was 1.5 g/dL.
Cross-matched-compatible packed red blood cell and plasma transfusions were administered immediately prior to surgery. Two mesenteric lymph nodes and approximately 60 cm of jejunum (and associated mesentery) were removed (Figures 2A, B) . The section of jejunum that was removed was orad to the ileocecocolic junction and aborad to the duodenum. Recovery from surgery was uneventful. Following surgery (within 24 hr), AMB was initiated.
The 
Discussion
The patient in this case presented with a long history of weight loss associated with nonresolving diarrhea that had recently escalated to include vomiting and melena. Additionally, the dog had long-standing panhypoproteinemia and anemia. To the authors' knowledge, this is the first reported case of panhypoproteinemia with resolution following treatment of intestinal cryptococcosis.
Furthermore, the authors of this report did not find any other reports describing terbinafine for the treatment regimen for cryptococcosis, emphasizing that this was a novel approach to the disease.
A previous report described cryptococcal infection of the gastric mucosa of a dog, which closely resembled a gastric mass in appearance. 6 Few other reports have described intra-abdominal infections as the sole location of the disease. However, after medical treatment failed to resolve the lesions, surgical therapy was pursued followed by a novel medical therapy,
terbinafine.
There are occasional reports of the development of resistance to fluconazole during long-term therapy for cryptococcosis in humans. 12 This may explain why the lesions in the case described Terbinafine has been documented to enter the central nervous system of rats. 13 In addition, terbinafine has been investigated in the treatment of rabbit coccidioidal meningitis, but it was not found in any appreciable concentration in the cerebrospinal fluid. success, whereas the other reported failure with a treatment protocol that used terbinafine. 17, 18 Another recent study investigated the pharmacokinetics of terbinafine in canines and revealed that plasma concentrations high enough to combat systemic fungal diseases can be achieved. 19 Side effects of terbinafine have not routinely been encountered in the canine species, but mild gastrointestinal upset can Although insufficient data are currently available to recommend terbinafine as a first-line agent, use in cases where primary therapy has failed to yield a response may prove beneficial.
Conclusion
The patient described in this report had an unusual presentation 
